Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
Bullous pemphigoid. New directions of therapy, prospects for the future (literature review)
https://doi.org/10.33667/2078-5631-2024-25-30-33
Abstract
Bullous pemphigoid (BP) is an autoimmune subepidermal bullous dermatosis that significantly affects the quality of life of patients due to pronounced subjective symptoms, affecting mainly the elderly. Autoantibodies against hemidesmosomal proteins BP180 and BP230 are involved in the pathogenesis of BP, which leads to detachment at the junction of the dermis and epidermis, as well as the formation of blisters. The severity, prevalence of the pathological process and painful itching require the appointment of high doses or constant use of systemic glucocorticoids, which is not always possible due to extensive concomitant pathology and a large list of side effects. The article presents modern methods of bullous pemphigoid therapy using monoclonal antibodies (rituximab, dupilumab, omalizumab). The mechanisms of therapeutic effect of the drugs described in the article are aimed at various pathways of immunopathogenesis of bullous pemphigoid. The new treatment methods described in the article offer alternative ways of helping patients who have contraindications to the appointment of systemic glucocorticosteroids, demonstrating the lack of effect from the use of basic therapy, with a recurrent process. New therapeutic techniques will improve results and reduce high cumulative doses of systemic corticosteroids and their associated toxic effects.
About the Author
E. V. Matushevskaya
Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
Elena V. Matushevskaya - DM Sci (habil.), professor at Dept of Dermatovenereology and Cosmetology of the Academy of Postgraduate Education.
Moscow
References
1. M.S.M. Persson, K. E. Harman, Y. Vinogradova, S. M. Langan, J. Hippisley-Cox, K. S. Thomas, S. Gran, Incidence, prevalence and mortality of bullous pemphigoid in England 1998–2017: a population-based cohort study, British Journal of Dermatology, Volume 184, Issue 1, 1 January 2021, Pages 68–77, https://doi.org/10.1111/bjd.19022
2. Mattie Rosi-Schumacher, John Baker, James Waris, Kristina Seiffert-Sinha, Animesh A. Sinha, Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid, Frontiers in Immunology. 2023(14). https://doi.org/10.3389/fimmu.2023.1159351
3. van Beek, N., Weidinger, A., Schneider et al. Incidence of pemphigoid diseases in Northern Germany in 2016 – first data from the Schleswig-Holstein Registry of Autoimmune Bullous Diseases. J Eur Acad Dermatol Venereol. 2021(35): 1197–1202. https://doi.org/10.1111/jdv.17107
4. Milinković MV, Janković S, Medenica L, Nikolić M, Reljić V, Popadić S, Janković J. Incidence of autoimmune bullous diseases in Serbia: a 20-year retrospective study. J Dtsch Dermatol Ges. 2016 Oct;14(10):995–1005. https://doi.org/10.1111/ddg.13081
5. Kridin K. Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations. Immunologic Research. 2018 Feb;66(1):6–17. https://doi.org/10.1007/s12026-017-8975-2
6. Oren-Shabtai M, Mimouni D, Nosrati A, Atzmony L, Kaplan B, Barzilai A and Baum S Biological treatment for bullous pemphigoid. Front. Immunol. 2023(14):1157250. https://doi.org/10.3389/fimmu.2023.1157250
7. Drozhdina MB, Bobro VA, Sennikova YA. Current approaches to the diagnosis of autoimmune bullous dermatoses. Vestnik Dermatologii i Venerologii. 2021;97(1):16–26. (In Russ.). https://doi.org/10.25208/vdv1185
8. Khalid SN, Khan ZA, Ali MH, Almas T, Khedro T, Raj Nagarajan V. A blistering new era for bullous pemphigoid: A scoping review of current therapies, ongoing clinical trials, and future directions. Ann Med Surg (Lond). 2021 Sep 4;70:102799. https://doi.org/10.1016/j.amsu.2021.102799
9. Drozhdina M. B., Koshkin S. V. Bullous pemphigoid. Сlinic, Diagnosis and Treatment. Vestnik Dermatologii i Venerologii. 2017(6):47–52. (In Russ.). https://doi.org/10.25208/0042-4609-2017-93-6-47-52
10. Drozhdina MB, Koshkin SV, Iutinskaya AO. Modern concept of the etiology, pathogenesis, clinical presentation, diagnosis, and treatment of Lever-type bullous pemphigoid. Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya. 2018;17(5):53–58. (In Russ.). https://doi.org/10.17116/klinderma20181705153
11. Persson MS, Harman KE, Thomas KS, Chalmers JR, Vinogradova Y, Langan SM, Hippisley-Cox J, Gran S. Long-term oral prednisolone exposure in primary care for bullous pemphigoid: population-based study. Br J Gen Pract. 2021 Nov 25;71(713): e904-e911. https://doi.org/10.3399/BJGP.2020.0870
12. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Care Res. 2006;55(3):420–426. https://doi.org/10.1002/art.21984
13. Van Staa T-P, Leufkens H, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93(2):105–111. https://doi.org/10.1093/qjmed/93.2.105
14. Abduelmula A, Mufti A, Chong DHY, Sood S, Prajapati VH, Yeung J. Biologic treatment outcomes in refractory bullous pemphigoid: An evidence-based review. JAAD Int. 2022 Sep 22; 9: 142–145. https://doi.org/10.1016/j.jdin.2022.09.001
15. Polansky M., Eisenstadt R., DeGrazia T., Zhao X., Liu Y., Feldman R. Rituximab therapy in patients with bullous pemphigoid: a retrospective study of 20 patients. J Am Acad Dermatol. 2019;81(1):179–186. https://doi.org/10.1016/j.jaad.2019.03.049
16. N. Kremer, I. Snast, E. S. Cohen, et al. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol, 2019 (20): 209–216. https://doi.org/10.1007/s40257-018-0401-6
17. N. Tovanabutra, A. S. Payne. Clinical outcome and safety of rituximab therapy for pemphigoid diseases. J Am Acad Dermatol, 2020 (82): 1237–1239, https://doi. org/10.1016/j.jaad.2019.11.023
18. D. S. Yoo, J. H. Lee, S. C. Kim, J. H. Kim. Mortality and clinical response of patients with bullous pemphigoid treated with rituximab. Br J Dermatol, 2021 (185):210–212. https://doi.org/10.1111/bjd.19890
19. Hendricks A. J., Yosipovitch G., Shi V. Y. Dupilumab use in dermatologic conditions beyond atopic dermatitis–a systematic review. J. Dermatol. Treat. 2021; 32: 19–28. https://doi.org/10.1080/09546634.2019.1689227
20. Yan T, Xie Y, Liu Y, Shan Y, Wu X, Wang J, Zuo Y-G and Zhang Z (2023) Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types. Front. Immunol. 14:1194088. https://doi.org/10.3389/fimmu.2023.1194088
21. Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, et al. Updated S 2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022; 36(10):1689–704. https://doi.org/10.1111/jdv.18220
22. Zeng FAP, Murrell DF. Bullous pemphigoid-What do we know about the most recent therapies? Front Med (Lausanne). 2022 Nov 3; 9: 1057096. https://doi.org/10.3389/fmed.2022.1057096
23. Cao P, Xu W, Zhang L. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review. Front Immunol. 2022 Jun 13; 13: 928621. https://doi.org/10.3389/fimmu.2022.928621
24. Kirtschig G., Middleton P., Bennett C., Murrell D. F., Wojnarowska F., Khumalo N. P. Interventions for bullous pemphigoid. The Cochrane database of systematic reviews. 2010;2010(10). https://doi.org/10.1002/14651858.CD002292.pub3.CD002292
25. de Graauw E., Sitaru C., Horn M., Borradori L., Yousefi S., Simon H. U., Simon D. Evidence for a role of eosinophils in blister formation in bullous pemphigoid. Allergy. 2017;72(7):1105–1113. https://doi.org/10.1111/all.13131
26. Kridin K. Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation. Br. J. Dermatol. 2018; 179: 1141–1147. https://doi.org/10.1111/BJD.16679
27. Cozzani E., Gasparini G., Di Zenzo G., Parodi A. Immunoglobulin E and bullous pemphigoid. European journal of dermatology: EJD. 2018;28(4):440–448. https://doi.org/10.1684/ejd.2018.3366
28. Amber K. T., Valdebran M., Kridin K., Grando S. A. The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease. Front. Med. 2018:201. https://doi.org/10.3389/FMED.2018.00201. 0
29. Fairley J. A., Baum C. L., Brandt D. S., Messingham K. A. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol. 2009;123(3):704–705. https://doi.org/10.1016/j.jaci.2008.11.035
30. Yu K. K., Crew A. B., Messingham K. A.M., Fairley J. A., Woodley D. T. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71(3):468–474. https://doi.org/10.1016/j.jaad.2014.04.053
31. Álvaro Aguado Vázquez, Andrea Estébanez Corrales, F Javier Melgosa et al. Efficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experience, Clinical and Experimental Dermatology, 2024; llae067, https://doi.org/10.1093/ced/llae067
32. Ling X, Shou X, Lou Y, Ling J, Zhang M, Yu T, et al. Research progress of omalizumab in the treatment of bullous pemphigoid. J Dermatol. 2023; 50: 575–587. https://doi.org/10.1111/1346–8138.16791
33. Lonowski S, Sachsman S, Patel N, Truong A, Holland V. Increasing evidence for omalizumab in the treatment of bullous pemphigoid. JAAD Case Rep. 2020 Feb 26;6(3):228–233. https://doi.org/10.1016/j.jdcr.2020.01.002
34. Maglie R, et al. The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets. Front Med (Lausanne) 2023; 10: 1128154. https://doi.org/10.3389/fmed.2023.1128154
35. Karakioulaki M, Eyerich K, Patsatsi A. Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update. Am J Clin Dermatol. 2024 Mar;25(2):195–212. https://doi.org/10.1007/s40257-023-00832-1
Review
For citations:
Matushevskaya E.V. Bullous pemphigoid. New directions of therapy, prospects for the future (literature review). Medical alphabet. 2024;(25):30-33. (In Russ.) https://doi.org/10.33667/2078-5631-2024-25-30-33
Views:
131
Email this article 